Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia |
| |
| Authors: | Stephen P Hunger MD Mignon L Loh MD James A Whitlock MD Naomi J Winick MD William L Carroll MD Meenakshi Devidas PhD Elizabeth A Raetz MD |
| |
| Institution: | 1. University of Colorado School of Medicine, The University of Colorado Cancer Center and Children's Hospital Colorado, Aurora, Colorado;2. Department of Pediatrics, University of California at San Francisco, San Francisco, California;3. Department of Paediatrics, University of Toronto and The Hospital for Sick Children, Haematology/Oncology, Toronto, Ontario, Canada;4. University of Texas Southwestern School of Medicine, Dallas, Texas;5. New York University Langone Medical Center and Cancer Institute, New York, New York;6. Department of Biostatistics, Children's Oncology Group Statistics & Data Center, and the University of Florida, Gainesville, Florida |
| |
| Abstract: | Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high‐risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T‐cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL. Pediatr Blood Cancer 2013; 60: 957–963. © 2012 Wiley Periodicals, Inc. |
| |
| Keywords: | acute lymphoblastic leukemia (ALL) COG ALL trials |
|
|
